<- Go Home

Repligen Corporation

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

Market Cap

$8.2B

Volume

597.7K

Cash and Equivalents

$809.1M

EBITDA

$78.9M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$287.3M

Profit Margin

47.70%

52 Week High

$211.13

52 Week Low

$110.45

Dividend

N/A

Price / Book Value

4.14

Price / Earnings

-4.3K

Price / Tangible Book Value

13.24

Enterprise Value

$8.2B

Enterprise Value / EBITDA

78.57

Operating Income

$8.4M

Return on Equity

-0.10%

Return on Assets

0.19

Cash and Short Term Investments

$809.1M

Debt

$742.9M

Equity

$2.0B

Revenue

$602.4M

Unlevered FCF

$123.3M

Sector

Life Sciences Tools and Services

Category

N/A

Company Stock Pitches